The wider community of liver stakeholders witnessed an exciting July as new compelling data and presentations were revealed across two major meetings, EASL Congress and the American Diabetes Association Scientific Sessions. Throughout that month, SurfingNASH provided real-time coverage and review of the emerging stories spanning topics like drug development, new nomenclature, omics and AI, NITs and more.
For this episode the trio of co-hosts, Jörn Schattenberg, Louise Campbell and Roger Green, embark on their first exclusive discussion together in a while without any guest panelists. The overarching theme of the program observes what has made 2023 interesting and exciting thus far before offering a look into what the audience can expect to learn more about in the imminent months.
This conversation starts with continued focus around the new nomenclature, but moves on quickly from there to Louise’s highlight of the year. She talks about how patients now play a larger role in all facets of education and drug development. Jörn agrees with this note and suggests that the level of patient involvement in this disease is far greater than what is observed elsewhere. Roger agrees with both statements, although expresses caveats about the need over time to move forward from simply including patient voices to actually listening to what they have to say and taking guidance from them with higher degree of success. From here, Roger introduces his highlight which is a combination of NIT development that will make these tests more pivotal on patient diagnosis management and, separately, new artificial intelligence modalities that utilize biopsy results to produce better pictures and a far more sophisticated level of disease understanding than we’ve had to date. Jörn and Louise both comment on issues they consider pivotal and highly valuable in terms of the use of NITs and lessons from AI.
Reviewing this episode and the various conversations is a strong reminder of how much information has already become available this year and what it portends in terms of future episodes and an ever-increasing explosion of new information about liver disease, drugs, testing, and so much more. If you have questions or comments around the EASL Congress or ADA meetings, the discussed therapeutics, new nomenclature, or any other topic addressed in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!
